Animal Cells TRIZ Cases

Cold-adapted subtilisin proteases maintain high activity at 4 to 20°C, overcoming the low stability of conventional enzymes in cold detergent compositions.

A recombinant polynucleotide encoding protoilludene synthase catalyzes farnesyl diphosphate cyclization to boost melleolide yields.

Isolated human monoclonal antibody 5C9 binds the thyrotropin receptor to block stimulating and blocking autoantibodies.

Antibodies bind specifically to pyroglutamate-modified amyloid beta oligomers, enabling precise differentiation of Alzheimer's patients from healthy controls.

Anti-LRP6 antibodies antagonize Dkk1 activity to restore Wnt signaling, addressing ineffective modulation of tissue repair in osteoporosis.

Specific residue mutations reduce protein aggregation while maintaining high DNA cytosine deaminase activity levels.

Creating MASP-2 deficient mammal models overcomes the complexity of genetic modification to enable targeted study of complement activation mechanisms.

TCR-enriched clonotypes identify protective immune responses to accelerate effective 2019-nCoV vaccine development.

Cryopreserved natural allograft intervertebral disk restores spinal mobility while preventing adjacent-segment degeneration.

Hybridizing surface nucleic acids patterns cells precisely, resolving the trade-off between mechanical complexity and tissue organization accuracy.

A feather tip bioassay system monitors avian immune responses through minimally invasive local injection and tissue analysis.

Hybrid promoters drive universal ferritin expression across tissues, enabling non-invasive MRI monitoring of multiple organs without contrast agents.

Specific amino acid substitutions in mutated DR5 antibodies resolve the contradiction between limited receptor affinity and desired biological activity.

Genetic cloning of the porcine pancreatic lipase gene enables mass production that overcomes the high cost and time required for traditional tissue extraction.

Isolating the Sf-fdl gene clarifies processing specificity, enabling mammalian-like glycan synthesis.

A triple-gene edited cloned pig model enables precise human physiological simulation for advanced biomedical studies.

Differentiated NG108-15 cells achieve mouse bioassay-level sensitivity for botulinum neurotoxin detection without animal testing.

Mechanical filtration through pores deforms cells for delivery while minimizing viability loss.

Sequential affinity chromatography isolates multiple plasma proteins using specific synthetic ligands attached to a support matrix.

A culture vessel with a concave-convex bottom surface uses centrifugal or magnetic force to assemble cells into three-dimensional tissue structures.

Segmented chambers replicate the in vivo environment to resolve the trade-off between mimicking biological fidelity and preserving single-cell resolution data.

Compact affibody molecules access confined transmembrane clefts to modulate signaling pathways, overcoming structural constraints of traditional antibodies.

Domain exchanged bispecific antibodies remove immunogenic linkers and invert pairing logic to resolve stability and manufacturing contradictions.

A cell capture assay selects high-producer CHO cell lines expressing recombinant anti-CD34 antibodies.

Stable hybridoma cell lines produce reproducible monoclonal antibodies to resolve standardization issues in Prox1 detection.

Genetically engineered mice express human NaV1.7 channels to enable in vivo therapeutic testing.

Humanized CD30 antibodies reduce immunogenicity by replacing murine frameworks with human sequences while preserving antigen-binding specificity.

Humanized A5 antibodies resolve cross-reactivity and human anti-murine responses while maintaining specific therapeutic reliability.

Optimized CRISPR editing of the WIZ gene increases fetal hemoglobin production while maintaining high targeting specificity in hematopoietic stem cells.

Antibodies targeting mesothelin kill tumor cells while sparing normal tissues through specific binding and internalization.

Internal ribosome entry sites enable co-expression of antibody chains and selection markers, minimizing non-expressing clones during CHO cell line generation.

Antibodies m921 and m922 target DR4 to induce apoptosis, overcoming TRAIL resistance and cytotoxicity.